The Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanoma-A Nation-Wide Swedish Population-Based Retrospective Register Study.
beta blocking agents
melanoma
survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Nov 2020
02 Nov 2020
Historique:
received:
10
09
2020
revised:
29
10
2020
accepted:
29
10
2020
entrez:
5
11
2020
pubmed:
6
11
2020
medline:
6
11
2020
Statut:
epublish
Résumé
Previous studies have demonstrated an anti-tumoral effect of beta-adrenergic blocking agents on cutaneous melanoma (CM). The aim of this study was to investigate if beta-adrenergic blocking agents have an impact on survival in Swedish patients with melanoma. A population-based retrospective registry study including all patients diagnosed with a primary invasive melanoma between 2009 and 2013 was performed. Data from the Swedish Melanoma Register were linked to the Swedish Prescribed Drug Registry and the Swedish Cause of Death Register. Cox regression analyses including competing risk assessments were performed. There were 12,738 patients included, out of which 3702 were exposed to beta-blockers vs. 9036 non-exposed patients. Age, male sex, Breslow thickness, ulceration, and nodal status were independent negative prognostic factors for melanoma-specific survival (MSS). Adding beta-blockers to the analysis did not add any prognostic value to the model (HR 1.00,
Identifiants
pubmed: 33147744
pii: cancers12113228
doi: 10.3390/cancers12113228
pmc: PMC7693684
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Knut och Alice Wallenbergs Stiftelse
ID : Wallenberg Centre for molecular and translational medicine
Références
Eur J Cancer. 2013 Dec;49(18):3863-71
pubmed: 23942335
N Engl J Med. 2019 Aug 15;381(7):626-636
pubmed: 31166680
Br J Dermatol. 2014 Apr;170(4):930-8
pubmed: 24593055
Arch Intern Med. 2011 Apr 25;171(8):779-81
pubmed: 21518948
J Invest Dermatol. 2015 Feb;135(2):525-531
pubmed: 25178102
Oncotarget. 2016 Nov 22;7(47):77825-77837
pubmed: 27788481
Curr Oncol Rep. 2018 Sep 24;20(11):87
pubmed: 30250984
Pharmacol Res Perspect. 2019 Jul 12;7(4):e00496
pubmed: 31338197
Gynecol Oncol. 2012 Nov;127(2):375-8
pubmed: 22819786
J Mol Med (Berl). 2013 Dec;91(12):1407-19
pubmed: 23907236
J Clin Oncol. 2011 Jul 1;29(19):2645-52
pubmed: 21632501
Br J Pharmacol. 2017 Jan;174(2):139-149
pubmed: 27792834
Ann Oncol. 2019 Apr 1;30(4):582-588
pubmed: 30715153
Front Immunol. 2018 Feb 06;9:164
pubmed: 29479349
Pharmacol Res. 2017 Oct;124:74-91
pubmed: 28712971
Drug Discov Today. 2015 Aug;20(8):1027-34
pubmed: 25975957
Oncotarget. 2016 Oct 18;7(42):68314-68327
pubmed: 27582542
Oncoimmunology. 2017 Dec 21;7(3):e1405205
pubmed: 29399407
Lab Invest. 2013 Mar;93(3):279-90
pubmed: 23318885
Cancers (Basel). 2020 Apr 28;12(5):
pubmed: 32353988
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
J Invest Dermatol. 2016 Jun;136(6):1161-1171
pubmed: 26902923
Breast Cancer Res Treat. 2011 Sep;129(2):549-56
pubmed: 21479924
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
Br J Anaesth. 2018 Jul;121(1):45-57
pubmed: 29935594
Recenti Prog Med. 2012 Jan;103(1):11-6
pubmed: 22322621
JAMA Oncol. 2018 Feb 8;4(2):e172908
pubmed: 28973254
Br J Cancer. 1996 May;73(9):1126-31
pubmed: 8624275